Switch View
© BusinessWire
03.11.2025
ISIN: US8688731004
Surmodics Inc
SRDX
LISTED
NASDAQ
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
News Preview
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extrem...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US08205P1003
Benitec Biopharma, Inc.
BNTC
LISTED
NASDAQ
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
News Preview
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today provides positive interim clinic...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
News Preview
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA)...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
03.11.2025
ISIN: US5011471027
Krystal Biotech Inc
KRYS
LISTED
NASDAQ
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
News Preview
$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
03.11.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US7473241013
Pyxis Oncology Inc
PYXS
LISTED
NASDAQ
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US88322Q1085
TG Therapeutics Inc
TGTX
LISTED
NASDAQ
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
News Preview
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US09058V1035
BioCryst Pharmaceuticals Inc
BCRX
LISTED
NASDAQ
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US5015751044
Kymera Therapeutics Inc
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
News Preview
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences to Participate in Upcoming Conferences
News Preview
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US1420381089
Caribou Biosciences Inc
CRBU
LISTED
NASDAQ
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
News Preview
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data from dose escalation in the ongoing CaMMouflage phase 1 trial evaluating CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in relapsed...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US61225M1027
Monte Rosa Therapeutics Inc
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
News Preview
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
03.11.2025
ISIN: US58502B1061
Pediatrix Medical Group Inc
MD
LISTED
NYSE
Pediatrix Medical Group Reports Third Quarter Results
News Preview
Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.84 per share for the three months ended September 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.67.
For the 2025 third quarter, Pediatrix reported the following results:
Net revenue of $493 million;
Net i...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: CA05156V1022
Aurinia Pharmaceuticals Inc
AUPH
LISTED
NASDAQ
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
News Preview
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025.
Aurinia’s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the we...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US09075V1026
Biontech SE
BNTX
LISTED
NASDAQ
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
News Preview
BioNTech SE today reported financial results for the three and nine months ended September 30, 2025 and provide an update on its corporate progress....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CA72706K1012
Planet 13 Holdings Inc.
PLTH
LISTED
CSE
Planet 13 Streamlines Footprint to Focus on Core Growth Markets
News Preview
Planet 13 Divests Non-Core Orange County Store and Closes Coalinga Cultivation Facility Planet 13 Divests Non-Core Orange County Store and Closes Coalinga Cultivation Facility...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US89854M1018
TScan Therapeutics, Inc.
TCRX
LISTED
NASDAQ
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
News Preview
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US53635D2027
Liquidia Corp
LQDA
LISTED
NASDAQ
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also ho...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US29358P1012
Ensign Group Inc
ENSG
LISTED
NASDAQ
The Ensign Group Expands in Utah
News Preview
SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced to...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US29358P1012
Ensign Group Inc
ENSG
LISTED
NASDAQ
The Ensign Group Adds Operation in Alabama
News Preview
SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced to...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: SE0002190926
Karolinska Development AB
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures
News Preview
Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a tranched convertible loan from Sound Bioventures.The investment supports continued clinical development of BT-101, a pioneering stem cell-based thera...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
News Preview
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb” or the “Offeror”), announced the commencement of tender offers (“Offers”) to purchase for cash certain of its outstanding notes (collectively, the “Notes”) as described in the tables below.
Pool 1
Offers to purchase for cash up to $4,000,000,000 aggregate purchase price for the sec...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investors Have Opportunity to Lead Molina Healthcare, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina" or "the Company") (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MOH
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina " or "the Company") (NYSE: MOH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US80303D3052
SANUWAVE Health, Inc.
SNWV
LISTED
NASDAQ
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
News Preview
CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Thomas Meier becomes new CEO of Medios AG
News Preview
Press release
Thomas Meier becomes new CEO of Medios AG
Berlin, November 3, 2025 – The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer (CEO) of the Company. He succeeds Matthias Gaertner, who will remain in office un......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Thomas Meier wird neuer Vorstandsvorsitzender der Medios AG
News Preview
Pressemitteilung
Thomas Meier wird neuer Vorstandsvorsitzender der Medios AG
Berlin, 3. November 2025 – Der Aufsichtsrat der Medios AG hat Thomas Meier mit Wirkung zum 1. Februar 2026 als Mitglied des Vorstands bestellt und zum neuen Vorsitzenden des Vorstands (CEO) der Gesellschaft ernannt. Er folgt Matthias Gärtner, der bis zum 31. Dezember 2025......
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on w...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 a...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus " or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: JP3256000005
Kyowa Kirin Co Ltd
41510
LISTED
XJPX
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
News Preview
Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical Company, today announced the appointment of Julie Dehaene-Puype as President for the Region, effective 1 November 2025. Julie follows the tenure of Jeremy Morgan, who has served as President for the I...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Ex...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company") (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulg...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
Avantor, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVTR
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Avantor, Inc. ("Avantor " or "the Company") (NYSE: AVTR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
AVTR Investors Have Opportunity to Lead Avantor, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avantor, Inc. ("Avantor" or "the Company") (NYSE: AVTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ISIN: MYQ0101OO004
TMC Life Sciences Bhd
TMCLIFE
LISTED
KLS
TMC Life Sciences Poised for Growth Through Strategic Partnerships and Value-Based Care
News Preview
EQS Newswire / 03/11/2025 / 08:30 CET/CEST
PETALING JAYA, MALAYSIA - Media OutReach Newswire - 3 November 2025 - TMC Life Sciences Berhad (TMCLS) remains on track for continued growth in FY2026, following a resilient FY2025 performance anchored by a commitment to clinical excellence, renewed engagement with insurance and corporate partners, st......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
03.11.2025
ISIN: US88066N3035
Tenon Medical, Inc.
TNON
LISTED
NASDAQ
Tenon Medical, Inc. Announces Timing of Third Quarter 2025 Financial Results
News Preview
LOS GATOS, CA / ACCESS Newswire / November 3, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced plans to release financial results for the third quarter 2025 ended September 30, 2025 after market close on Th...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
03.11.2025
ISIN: US60785L2079
Modular Medical, Inc.
MODD
LISTED
NASDAQ
Modular Medical Announces Successful Validation of Controller Line for Pivot Insulin Delivery System
News Preview
Key Highlights:Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch.Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch pump, targets the $3 billion dollar market for adult "almost-pumpers" with its affordable, u...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Nov. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. (MOH) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Robbins Geller Rudman & Dowd LLP
News Preview
SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Molina Healthcare, Inc. (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), have until Tuesday, December 2, 2025 to seek...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA (AEVS.SW) – Continued revenue growth in the third quarter of 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Fribourg, 3 November 2025
AEVIS VICTORIA SA (AEVS.SW) – Continued revenue growth in the third quarter of 2025
Consolidated growth of 18.2%, driven by the Healthcare and Hospitality divisions. Adjusted organic growth of 2.6%.
AEVIS VICTORIA SA (AEVIS) achieved consolidated gross revenue of CHF 899.2 mi......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.11.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA (AEVS.SW) – Weiteres Umsatzwachstum im dritten Quartal 2025
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR
Freiburg, 3. November 2025
AEVIS VICTORIA SA (AEVS.SW) – Weiteres Umsatzwachstum im dritten Quartal 2025
Konsolidiertes Wachstum von 18.2%, getragen von den Bereichen Healthcare und Hospitality. Bereinigtes organisches Wachstum von 2.6%.
AEVIS VICTORIA SA (AEVIS) erzielte in den ersten neun Monaten 2025 einen......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
03.11.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
News Preview
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants with relapsed or refractory multiple myeloma (RRMM). The first dose was administered at SCRI Oncology...
Themefolio
Profiler
Peergroup
© Newsfile
03.11.2025
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Receives CE Certification for ColonPRO EU - The Most Advanced AI Software Platform for Colonoscopy in Europe
News Preview
Dublin, Ireland--(Newsfile Corp. - November 3, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that ColonPRO EU, the Company’s next-generation artificial intelligence software for colonoscopy, has received CE certification. Following FDA clearance in the...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: KR7006280002
Green Cross Corporation
006280
LISTED
KOE
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
News Preview
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRAX is the world's...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
News Preview
Dosimetry portfolio strengthened with Medical Imaging QA and AI validation ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CH0256379097
Molecular Partners AG
MOLN
LISTED
SIX
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
News Preview
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CH0256379097
Molecular Partners AG
MOLN
LISTED
SIX
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
News Preview
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
News Preview
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer
News Preview
HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been granted Breakthrough Therapy Designation (BTD) by t...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 2, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) be...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US08205P1003
Benitec Biopharma, Inc.
BNTC
LISTED
NASDAQ
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
News Preview
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: KYG4672N1198
HUTCHMED (China) Ltd
13
LISTED
HKSE
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
News Preview
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
News Preview
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Applic...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
News Preview
REYKJAVIK, ICELAND (November 2, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.11.2025
ISIN: US1420381089
Caribou Biosciences Inc
CRBU
LISTED
NASDAQ
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
News Preview
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
